Details for Patent: 12,329,851

« Back to Dashboard

Which drugs does patent 12,329,851 protect, and when does it expire?

Patent 12,329,851 protects UZEDY and is included in one NDA.

This patent has ten patent family members in ten countries.

Summary for Patent: 12,329,851

Title:	Long acting injectable formulation comprising risperidone and biodegradable polymers
Abstract:	The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof at a frequency of no more than once every 28 days an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.
Inventor(s):	Avia Merenlender Wagner, Anna Elgart VALITSKY, Eran HARARY
Assignee:	MedinCell SA
Application Number:	US18/585,349
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 12,329,851

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-001	Apr 28, 2023		RX	Yes	Yes	12,329,851					A METHOD OF SWITCHING A PATIENT FROM DAILY ORAL RISPERIDONE THERAPY TO A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-002	Apr 28, 2023		RX	Yes	Yes	12,329,851					A METHOD OF SWITCHING A PATIENT FROM DAILY ORAL RISPERIDONE THERAPY TO A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-003	Apr 28, 2023		RX	Yes	Yes	12,329,851					A METHOD OF SWITCHING A PATIENT FROM DAILY ORAL RISPERIDONE THERAPY TO A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-004	Apr 28, 2023		RX	Yes	Yes	12,329,851					A METHOD OF SWITCHING A PATIENT FROM DAILY ORAL RISPERIDONE THERAPY TO A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-005	Apr 28, 2023		RX	Yes	Yes	12,329,851					A METHOD OF SWITCHING A PATIENT FROM DAILY ORAL RISPERIDONE THERAPY TO A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-006	Apr 28, 2023		RX	Yes	Yes	12,329,851					A METHOD OF SWITCHING A PATIENT FROM DAILY ORAL RISPERIDONE THERAPY TO A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION

International Family Members for US Patent 12,329,851

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2022236485
Brazil	112023018652
Canada	3208006
China	116997323
European Patent Office	4308077
Israel	304980